Literature DB >> 33666651

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib.

Cheryl A C Peretz1,2,3, Lisa H F McGary1, Tanya Kumar1, Hunter Jackson4, Jose Jacob5, Robert Durruthy-Durruthy5, Mark J Levis6, Alexander Perl7, Benjamin J Huang3,8, Catherine C Smith1,8.   

Abstract

Mesh：

Substances：

Year:  2021        PMID： 33666651      PMCID： PMC7948271          DOI： 10.1182/bloodadvances.2020003398

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  21 in total

1.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Authors:  Jorge Cortes; Alexander E Perl; Hartmut Döhner; Hagop Kantarjian; Giovanni Martinelli; Tibor Kovacsovics; Philippe Rousselot; Björn Steffen; Hervé Dombret; Elihu Estey; Stephen Strickland; Jessica K Altman; Claudia D Baldus; Alan Burnett; Alwin Krämer; Nigel Russell; Neil P Shah; Catherine C Smith; Eunice S Wang; Norbert Ifrah; Guy Gammon; Denise Trone; Deborah Lazzaretto; Mark Levis
Journal:  Lancet Oncol       Date:  2018-05-31       Impact factor: 41.316

2.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

3.  Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

Authors:  Catherine C Smith; Amy Paguirigan; Grace R Jeschke; Kimberly C Lin; Evan Massi; Theodore Tarver; Chen-Shan Chin; Saurabh Asthana; Adam Olshen; Kevin J Travers; Susana Wang; Mark J Levis; Alexander E Perl; Jerald P Radich; Neil P Shah
Journal:  Blood       Date:  2017-05-10       Impact factor: 22.113

4.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.

Authors:  Charissa Kim; Ruli Gao; Emi Sei; Rachel Brandt; Johan Hartman; Thomas Hatschek; Nicola Crosetto; Theodoros Foukakis; Nicholas E Navin
Journal:  Cell       Date:  2018-04-19       Impact factor: 41.582

5.  Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

Authors:  Martin Carroll; Catherine C Smith; Alexander E Perl; Christine M McMahon; Timothy Ferng; Jonathan Canaani; Eunice S Wang; Jennifer J D Morrissette; Dennis J Eastburn; Maurizio Pellegrino; Robert Durruthy-Durruthy; Christopher D Watt; Saurabh Asthana; Elisabeth A Lasater; RosaAnna DeFilippis; Cheryl A C Peretz; Lisa H F McGary; Safoora Deihimi; Aaron C Logan; Selina M Luger; Neil P Shah
Journal:  Cancer Discov       Date:  2019-05-14       Impact factor: 39.397

6.  Tumour evolution inferred by single-cell sequencing.

Authors:  Nicholas Navin; Jude Kendall; Jennifer Troge; Peter Andrews; Linda Rodgers; Jeanne McIndoo; Kerry Cook; Asya Stepansky; Dan Levy; Diane Esposito; Lakshmi Muthuswamy; Alex Krasnitz; W Richard McCombie; James Hicks; Michael Wigler
Journal:  Nature       Date:  2011-03-13       Impact factor: 49.962

7.  Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Authors:  Sharyn D Baker; Eric I Zimmerman; Yong-Dong Wang; Shelley Orwick; Douglas S Zatechka; Jassada Buaboonnam; Geoffrey A Neale; Scott R Olsen; Eric J Enemark; Sheila Shurtleff; Jeffrey E Rubnitz; Charles G Mullighan; Hiroto Inaba
Journal:  Clin Cancer Res       Date:  2013-08-22       Impact factor: 12.531

8.  Intra-tumour diversification in colorectal cancer at the single-cell level.

Authors:  Sophie F Roerink; Nobuo Sasaki; Henry Lee-Six; Matthew D Young; Ludmil B Alexandrov; Sam Behjati; Thomas J Mitchell; Sebastian Grossmann; Howard Lightfoot; David A Egan; Apollo Pronk; Niels Smakman; Joost van Gorp; Elizabeth Anderson; Stephen J Gamble; Chris Alder; Marc van de Wetering; Peter J Campbell; Michael R Stratton; Hans Clevers
Journal:  Nature       Date:  2018-04-11       Impact factor: 49.962

9.  Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Authors:  Haijiao Zhang; Samantha Savage; Anna Reister Schultz; Daniel Bottomly; Libbey White; Erik Segerdell; Beth Wilmot; Shannon K McWeeney; Christopher A Eide; Tamilla Nechiporuk; Amy Carlos; Rachel Henson; Chenwei Lin; Robert Searles; Hoang Ho; Yee Ling Lam; Richard Sweat; Courtney Follit; Vinay Jain; Evan Lind; Gautam Borthakur; Guillermo Garcia-Manero; Farhad Ravandi; Hagop M Kantarjian; Jorge Cortes; Robert Collins; Daelynn R Buelow; Sharyn D Baker; Brian J Druker; Jeffrey W Tyner
Journal:  Nat Commun       Date:  2019-01-16       Impact factor: 17.694

10.  Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.

Authors:  Tomoya Aikawa; Noriko Togashi; Koichi Iwanaga; Hiroyuki Okada; Yumi Nishiya; Shinichi Inoue; Mark J Levis; Takeshi Isoyama
Journal:  Oncotarget       Date:  2020-03-17
View more
  2 in total

Review 1.  Resistance to targeted therapies: delving into FLT3 and IDH.

Authors:  Sai Prasad Desikan; Naval Daver; Courtney DiNardo; Tapan Kadia; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2022-06-09       Impact factor: 9.812

2.  Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Authors:  Alexander E Perl; Naoko Hosono; Pau Montesinos; Nikolai Podoltsev; Giovanni Martinelli; Nicki Panoskaltsis; Christian Recher; Catherine C Smith; Mark J Levis; Stephen Strickland; Christoph Röllig; Marco Groß-Langenhoff; Wen-Chien Chou; Je-Hwan Lee; Hisayuki Yokoyama; Nahla Hasabou; Qiaoyang Lu; Ramon V Tiu; Jessica K Altman
Journal:  Blood Cancer J       Date:  2022-05-30       Impact factor: 9.812
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.